Press Releases

Back to Investors

August 2022

August 24 - Nurosene Appoints Neurosurgeon Dr. Douglas James Cook as Chief Medical Officer

August 23 - Nurosene Appoints New Advisory Board Member Dhananja Jayalath

July 2022

July 22 - Nurosene Appoints Industry Veteran Dr. Luca Pani as Chief Innovation and Regulatory Officer

July 19 - Nurosene Announces Appointment of New CFO

July 14 - Nurosene Appoints Seasoned Executive Josh Spiegel as President of Netramark

July 6 - Nurosene Announces Agreement with Denovo Biopharma LLC to Optimize Treatment-Resistant Depression Trial

June 2022

June 22 - Nurosene Enters Into Agreement with Taylored Biotherapeutics to Evaluate Clinical Trial Results

June 8 - Nurosene Health Inc. Announces Closing of Private Placement

June 8 - Nurosene's Chief Scientific Officer to Present at World Orphan Drug Congress USA 2022

May 2022

May 27 - Nurosene Enters Into Agreement with a Speciality Biopharma Company to Generate Insights from Clinical Trial Results

May 19 - Nurosene's Chief Scientific Officer Publishes Paper on AI and Placebo Response

May 18 - Nurosene Completes Population Stratification Project For Major Pharmaceutical Company

May 6 - Nurosene Announces Strategic Agreement with Brain Analysis Platform, Cove Neurosciences Inc.

April 2022

April 19 - Nurosene Initiates Research on Nuro App in Collaboration with Dalhousie University

April 13 - Nurosene Announces Research Partnership in Oncology with The Ontario Institute for Cancer Research

April 7 - Nurosene Appoints Seasoned Finance Executive Gino DeMichele to Board of Directors

March 2022

March 8 - Nurosene's CSO And Director Of Bioinformatics Receives 'Highly Cited Paper' Award For AI-Based Alzheimer's Research Findings

March 1 - Nurosene Advances Brain Health with the Launch of its Science First Nuro App

February 2022

February 23 - Nurosene Announces a Change in Leadership

February 17 - Nurosene Launches NetraPlacebo, an Innovative AI Technology to Impact Clinical Trial Success Rates in the US$94B Central Nervous System (CNS) Therapeutics Market

February 10 - Nurosene & Cyclica Partner To Develop Novel Drugs For Neurodegenerative Diseases

February 4 - Nurosene Health Inc. Announces Change to its Board of Directors

January 2022

January 27 - Nurosene Announces Research Partnership designed to Accelerate and Identify Novel Drug Candidates for its IP Portfolio

January 26 - Nurosene Health Inc. Reports 2021 Annual Financial Results and Provides Shareholder Update

January 6 - Nurosene to Present at the H.C. Wainwright Bioconnect Virtual Investor Conference on January 10-13, 2022

December 2021

December 16 - Nurosene CSO Awarded For Research on Placebo Response Related to Mental Health

December 13 - Nurosene Announces George Achilleos as President & Chief Operating Officer

December 9 - Nurosene Announces Extension of Voluntary Lock-up Agreements with Company Founder and Early Investors

December 2 - Nurosene to Present at the SNN Network Canada Virtual Event on Thursday, December 9, 2021

November 2021

November 29 - Nurosene Partners With Brain Computer Interface Technology Ni2o to Pioneer Research for Alzheimer's and ALS

November 23 - Nurosene Releases Preliminary Findings that Support the Innovation of Anti-Aging Therapeutics

November 22 - Nurosene Appoints Seasoned Tech Executive and Philanthropist Kevin Taylor as Chairman of the Board

November 18 - Nurosene's Chief Scientific Officer to Present at Notable International Society for CNS Clinical Trial and Methodology (ISCTM) Symposium

November 16 - Nurosene to Present at the Canaccord Genuity 3rd Annual Health & Wellness Virtual Conference

November 15 - Nurosene Appoints Mark Smithyes as President of Wholly-Owned Subsidiary, Netramark, A Leading AI Pharmatech Company

November 11 - Global Pop Icon Nick Jonas Invests in AI-driven Mental Health Company Nurosene

November 9 - Nurosene's Chief Scientific Officer, Dr. Joseph Geraci, to Present Cutting Edge Research on ALS Hosted by Google Subsidiary

November 2 - Nurosene Extracts Scientific Data from Nuro App Users Utilizing Netra-AI

October 2021

October 21 - Nurosene Health Completes Acquisition of Pharma AI Leader Netramark

October 18 - Nurosene Appoints NetraMark Co-Founder Dr. Joseph Geraci PhD as Chief Scientific Officer

October 12 - Nurosene Health Inc. Signs Definitive Agreement to Acquire NetraMark, a Leading AI and Quantum Computing Company

October 4 - Nurosene Adds Marketing and Healthcare Executive Raja Rajamannar as Honorary Advisor

September 2021

September 30 - Nurosene Adds NHL Star James van Riemsdyk to its Mental Health Advisory Council

September 28 - Nurosene to Present at the Benzinga Healthcare Small Cap Conference

September 27 - Nurosene Announces DTC Eligibility

September 8 - Nurosene to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

August 2021

August 30 - Nurosene Health Inc. Reports Fiscal Third Quarter 2021 Financial Results and Provides Shareholder Update

August 25 - Nurosene Appoints George Achilleos as Chief Operating Officer

August 10 - Nurosene Health Inc. Enters Into a Non-Binding Letter of Intent With Netramark Corp. for Proposed Acquisition

August 3 - Nurosene to Present at the 41st Annual Canaccord Genuity Virtual Growth Conference

July 2021

July 26 - Nurosene Receives Approval from Health Canada for Distribution of Nutraceutical Supplements

July 6 - Former Apple Global Head of eCommerce Solutions Marcus Delano East Joins Nurosene Advisory Board

July 2 - Nurosene Commences Trading on the Frankfurt Stock Exchange

June 2021

June 30 - Nurosene Enters Into Strategic Partnership to Accelerate Growth Into Mass Retail

June 28 - Former Director General of the Italian Medicines Agency (AIFA) Dr. Luca Pani Joins Nurosene As Chief Medical Advisor

June 23 - Nurosene Makes Strategic Executive Engineering Hire to Evolve the Future of the Nuro Application

June 17 - Nurosene Announces Launch of Precision Nutraceutical Supplements Designed to Build Better Brains

June 17 - Nurosene Creates Mental Health Advisory Council to Tackle Global Mental Health Crisis

June 10 - Nurosene Retains KCSA Strategic Communications for Investor Relations Services

June 9 - NFL Superstar Richard Sherman Invests in Mental Wellness Company Nurosene's IPO

June 9 - Nurosene Health Inc. Commences Trading on the CSE

June 8 - Nurosene Health Inc. Announces Closing of Oversubscribed Initial Public Offering

May 2021

May 25 - Nurosene Health Inc. Files Final Prospectus and Announces Receipt of Conditional Approval for CSE Listing (CNSX: MEND)